OCC Shares Orthocell Limited
ASX · ASXLast in our picks 2026-10-19 — not in the current list; analysis below is from that screen
Regenerative-medicine products and international expansion could support strong revenue growth.
Future value: $1.14 (+76.74%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Analyst Buy support and international commercialization.
- ▾Below 50-day MA (-12.73%)
- ▾Near 52-week low (2% of range)
- ▸~77% upside to price target
Is OCC a buy right now?
Trend: OCC is trading below the 50-day average (-23.57%), RSI 45 — neutral momentum, with a 3-month return of -26.71%.
Valuation & quality: Orthocell Limited trades on forward P/E -22.8, price-to-book 4.25; fundamentals show net margin -122.0%, return on equity -56.8%, revenue growth 42.3% year on year.
Analyst consensus: 2 analysts have a mean 12-month price target of A$0.90 (+68.2% vs the last close; range A$0.65 – A$1.15), consensus rating “buy”.
Our screen: BUY (score 3) — Regenerative-medicine products and international expansion could support strong revenue growth.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -15.80% | +11.30% | -14.60% | -3.90% | +0.00% | +4.10% | +0.00% | -28.90% |
Fundamentals
Analyst price target
Technical signals
About Orthocell Limited
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.